ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 297 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,199,387 | -35.1% | 267,934 | -13.9% | 0.02% | -32.1% |
| Q2 2023 | $11,091,686 | +383.6% | 311,040 | +244.5% | 0.03% | +300.0% |
| Q1 2023 | $2,293,620 | +305.5% | 90,300 | +547.5% | 0.01% | +250.0% |
| Q4 2022 | $565,609 | -62.5% | 13,945 | -67.5% | 0.00% | -60.0% |
| Q2 2022 | $1,510,000 | +395.1% | 42,886 | +546.9% | 0.01% | +400.0% |
| Q1 2022 | $305,000 | -95.0% | 6,629 | -91.1% | 0.00% | -92.9% |
| Q2 2021 | $6,145,000 | +78.7% | 74,200 | +43.1% | 0.01% | +55.6% |
| Q1 2021 | $3,439,000 | +150.5% | 51,862 | +63.2% | 0.01% | +28.6% |
| Q2 2020 | $1,373,000 | -91.7% | 31,787 | -94.4% | 0.01% | -94.8% |
| Q1 2020 | $16,468,000 | +65.9% | 572,403 | +265.9% | 0.13% | +346.7% |
| Q4 2019 | $9,924,000 | +120.1% | 156,451 | -33.5% | 0.03% | +150.0% |
| Q3 2018 | $4,509,000 | +76.0% | 235,216 | +24.9% | 0.01% | +50.0% |
| Q2 2018 | $2,562,000 | +1654.8% | 188,364 | +374.2% | 0.01% | – |
| Q4 2017 | $146,000 | – | 39,726 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |